Flynn Pharma focuses on the acquisition, development and commercialisation of proprietary products for the secondary healthcare and related markets.
Flynn's goal is to be the foremost European provider of specialty products in these targeted and underserved therapeutic categories.
Flynn has been structured and financed to pursue a rapid growth strategy in these sectors, offering superior service for our customers and value for our shareholders.
Our focus at Flynn Pharma is on prescription pharmaceutical products.
Under-promoted brands from other pharmaceutical companies, who often have numerous products that are too small for them, or are no longer of strategic importance.
In-licensing of late stage development products from R&D companies in specialist areas.